Extraordinary General Meeting of Q-Med Aktiebolag (publ)

At the request of Galderma Holding AB, a wholly owned subsidiary of Galderma
Pharma S.A. which after completion of its public offer to the shareholders of Q-
Med AB ("Q-Med" or the "Company") owns more than nine-tenths of the shares in Q-
Med, the shareholders of Q-Med are hereby invited to attend the Extraordinary
General Meeting on Monday 28 March, 2011 at 3 p.m. on Q-Med's premises. Entrance
from Fyrisvallsgatan 7, Uppsala.

Notification of intention to attend
Shareholders who wish to attend must
- both be entered in the register of shareholders maintained by Euroclear
Sweden  AB on Tuesday 22 March 2011,
- and notify the Company no later than on Tuesday 22 March 2010, preferably
before noon. This shall be done through Camilla Schartau, either in writing to
Q-Med AB, Seminariegatan 21, 752 28 Uppsala, by fax (+46 18 474 90 97), via e-
mailcamilla.schartau@q-med.com or by telephone (+46 18 474 90 00). Shareholders
should give their name, personal identity number or corporate identity number,
address and telephone number (daytime) and registered shareholding. Shareholders
who wish to be accompanied by one or two advisors should give notice of this
when they notify the Company of their intention to attend the meeting.

Shareholders who are represented by another party must issue a written proxy for
the representative. If the proxy has been issued by a legal entity, a copy of
the certificate of incorporation must be attached. Anyone representing a legal
entity must show a copy of the certificate of incorporation. The proxy and/or
certificate of incorporation should be sent to the Company in good time before
the Extraordinary General Meeting.

In order to be entitled to attend the Extraordinary General Meeting,
shareholders whose shares are registered in the name of a nominee through a bank
or another nominee must temporarily re-register the shares in their own name
with Euroclear Sweden AB. Such re-registration must have been completed by
Tuesday 22 March 2011 at the latest. Requests to have shares re-registered
should be made in good time before the above-mentioned date.

Proposal for agenda
At the Extraordinary General Meeting, the following matters will be dealt with.
1. Opening of the Extraordinary General Meeting.
2. Election of the Chair for the meeting.
3. Drawing up and approval of the voting list.
4. Approval of the agenda for the meeting.
5. Election of one or two people to verify the minutes.
6. Consideration of whether the meeting has been duly convened.
7. Determination of the number of Board members.
8. Determination of fees for each Board member.
9. Election of members of the Board.
10. Resolution regarding election committee.
11. Resolution regarding principles for remuneration and other conditions of
employment for senior management.
12. Closing of the Extraordinary General Meeting.


Q-Med AB is a medical device company that develops, manufactures, markets, and
sells high quality medical implants for esthetic and medical use. The majority
of the products are based on the company's patented technology, NASHA(TM), for
the production of stabilized non-animal hyaluronic acid. The product portfolio
today contains: Restylane® for filling lines and folds, contouring and creating
volume in the face, Macrolane(TM) for body contouring, Durolane(TM) for the
treatment of osteoarthritis of the hip and knee joints, Deflux® for the
treatment of vesicoureteral reflux, VUR, (a malformation of the urinary bladder)
in children, and Solesta® for the treatment of fecal incontinence. Sales are
made through the company's own subsidiaries or distributors in over 70
countries. Q-Med has about 650 coworkers, with almost 400 at the company's head
office and production facility in Uppsala, Sweden. Q-Med AB is listed in the Mid
Cap segment of the NASDAQ OMX Nordic.


Q-Med AB (publ), Seminariegatan 21, SE-752 28 Uppsala, Sweden. Corporate
identity number 556258-6882.
Tel: +46 18 474 90 00. Fax: +46 18 474 90 01. E-mail:info@q-med.com. Web: www.q-
med.com


Proposal for resolutions
Regarding item 2 and items 7-11 above, the Company has been informed that
Galderma will present proposals for resolutions by no later than at the
Extraordinary General Meeting.

Miscellaneous
As at the date of this notice, the total number of shares and votes in the
Company is 99,382,000. The Company holds no treasury shares.
If requested by a shareholder and the Board considers that it can take place
without causing material damage to the Company, the Board and the CEO will
provide information about both circumstances that may affect the assessment of
an item on the agenda, and circumstances that may affect the assessment of the
Company's relationship with another Group company. The Company provides a form
of proxy and will provide one by ordinary mail to shareholders who request one.

Uppsala in March 2011
Q-Med AB (publ)
The Board


Queries should be addressed to:
Alexander Kotsinas, CFO
Tel: +46 73 500 111
Carina Bolin, General Counsel
Tel: +46 70 974 9117


The information in this press release is such as that which Q-Med is required to
disclose in accordance with the Swedish Securities Market Act and/or the
Financial Instruments Trading Act. The information was submitted for disclosure
at 7.40 p.m. on March 3, 2011.

[HUG#1494463]